## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report the first structural characterization of the peptide CORO1C-47aa, encoded by circular RNA hsa-circ-0000437, using computational structure prediction, molecular dynamics refinement, and docking simulations with its binding partner ARNT. They further claim identification of putative ligand binding sites and propose a mechanistic link to endometrial cancer.
- **Visible evidence base** Abstract text only; no structural models, simulation parameters, docking scores, or validation metrics are provided
- **Missing materials affecting confidence** Full methods, structural coordinates, simulation trajectories, docking results, validation statistics, and any experimental corroboration

## Reviewer
- **Overall assessment** The abstract presents a purely computational study aimed at characterizing the structure and binding modes of a peptide of potential biomedical relevance. The topic is of interest to the circular RNA and cancer biology communities, and the work addresses a genuine gap in structural knowledge. However, the abstract provides no quantitative results, no validation of the computational predictions, and no clear evidence that the proposed mechanistic link to endometrial cancer is supported by the data. As presented, the claims are largely programmatic rather than demonstrated.
- **Who would be interested in the results, and why** Researchers studying circular RNA-encoded peptides, structural biologists interested in peptide-protein interactions, and investigators working on endometrial cancer biology or ARNT-related signaling pathways. The work may also be of interest to computational biologists developing or applying structure prediction and docking pipelines for small peptides.
- **Major strengths** The study addresses a clearly defined gap in knowledge, namely the absence of structural information for CORO1C-47aa. The computational approach is appropriate for a first-pass structural characterization. The connection to a clinically relevant process, endometrial cancer, gives the work translational relevance.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence sufficiency
  - **Claim pointer** The authors claim that this is the first report on the structural characterization of the peptide and its modes of interactions with ARNT.
  - **Evidence pointer** Abstract; location not provided
  - **Concern** The abstract states that structures were predicted and refined by molecular dynamics and that docking simulations were performed, but no results are presented. There are no structural models, no simulation details, no docking scores, no binding poses, and no comparison with known structures or experimental data.
  - **Why it matters** A claim of first structural characterization requires at least a minimal presentation of the resulting structure and its validation. Without any quantitative or qualitative results, the claim cannot be assessed.
  - **Resolution test** Provide the predicted structure, its confidence metrics, and docking results with ARNT, including binding affinity estimates and interaction details.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Claim support
  - **Claim pointer** The authors propose a plausible mechanism of involvement of the peptide in the onset of endometrial cancer.
  - **Evidence pointer** Abstract; location not provided
  - **Concern** The abstract does not describe any mechanistic analysis. It is unclear how structure prediction and docking translate into a cancer mechanism. No pathway analysis, functional assays, or literature-based mechanistic reasoning is presented.
  - **Why it matters** The mechanistic claim is a central part of the stated aim and is likely to be of interest to the readership. Without supporting evidence or a clearly articulated hypothesis, the claim is unsupported.
  - **Resolution test** Present a clearly reasoned mechanistic model based on the docking results and known ARNT biology, or temper the claim to reflect hypothesis generation rather than demonstrated mechanism.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Technical validation
  - **Claim pointer** The authors state that the structure was refined by molecular dynamics simulations and that docking simulations were performed.
  - **Evidence pointer** Abstract; location not provided
  - **Concern** No details are given on the methods used for structure prediction, the force field, simulation length, convergence criteria, or docking algorithm. Without these, the technical soundness of the approach cannot be evaluated.
  - **Why it matters** Computational predictions are highly method-dependent. The absence of methodological detail prevents assessment of reliability and reproducibility.
  - **Resolution test** Include full methodological details in the manuscript, including software versions, parameters, and validation steps.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity
  - **Affected element** Terminology
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The abstract refers to the peptide as having anti-angiogenic activity and being associated with prevention of endometrial cancer, but later states the study aims to elucidate its involvement in the onset of endometrial cancer. This is potentially contradictory.
  - **Required correction** Clarify whether the peptide is protective or pathogenic in the context of endometrial cancer, and ensure the language is consistent throughout.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Completeness
  - **Affected element** Ligand binding site analysis
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The abstract mentions analysis of possible ligand binding sites and natures of possible ligands, but no results are described.
  - **Required correction** Provide a summary of the predicted binding sites and the types of ligands predicted to bind, or state that this analysis is presented in the full manuscript.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Language precision
  - **Affected element** Phrasing
  - **Evidence pointer** Abstract; location not provided
  - **Issue** The phrase "structure function analysis study" is awkward and could be more precise.
  - **Required correction** Rephrase to something like "structure-function analysis" or "computational structural analysis."
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking. The absence of any presented results or mechanistic reasoning means the core claims of the abstract are not currently supported by the provided material.
- **Assessment against Nature-style criteria**  
  Originality: The work addresses a novel peptide with no prior structural data, which is a point in its favor. However, the abstract does not demonstrate what is new beyond the subject itself.  
  Scientific importance: The potential relevance to endometrial cancer is of interest, but the importance is not established without mechanistic evidence.  
  Interdisciplinary readership: The topic bridges circular RNA biology, structural biology, and cancer research, which could attract a broad audience.  
  Technical soundness: Cannot be assessed from the abstract alone. No methods or validation are presented.  
  Readability for nonspecialists: The abstract is generally readable, though some terms such as PAS-B domain and ARNT are used without explanation.
- **Recommendation posture** Currently not established from the provided evidence. The abstract describes a study plan rather than reporting results. If the full manuscript provides structural models, validation, docking results, and a clearly reasoned mechanistic hypothesis, the work could be considered supportive. As it stands, the claims are not assessable.

## Risk / unsupported claims
- The claim of being the first structural characterization of CORO1C-47aa is unsupported because no structural results are presented.
- The proposed mechanism of involvement in endometrial cancer is unsupported because no mechanistic analysis is described.
- The identification of ligand binding sites and ligand types is mentioned but not demonstrated.
- The potential utility for drug candidate design is speculative and not supported by any data in the abstract.